Anumana is a company that is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Pulse 2.0 interviewed Anumana CEO Maulik Nanavaty to learn more about the company.
Anumana: Interview With CEO Maulik Nanavaty About The AI-Driven Health Technology Company
Related Articles
Anumana and Novartis partner for AI-based heart disease detection
NS Medical Devices: Health technology company Anumana has entered into a multi-year strategic collaboration with Novartis Pharmaceuticals to detect heart disease leveraging a series of artificial intelligence (AI)-powered software solutions.…July 13, 2022
Tackling Imbalanced Regression in Clinical AI with KDE-weighted Deep Models
Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…June 15, 2025
Fierce Medtech’s 2022 Fierce 15
Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of…March 20, 2023
AI Algorithm Aids Early Detection of Low Ejection Fraction
Health Day: An artificial intelligence (AI) algorithm that uses data from electrocardiography can help increase the diagnosis of low ejection fraction (EF), according to a study published online May 6…May 27, 2021